286 related articles for article (PubMed ID: 23284610)
1. CSF and brain structural imaging markers of the Alzheimer's pathological cascade.
Yang X; Tan MZ; Qiu A
PLoS One; 2012; 7(12):e47406. PubMed ID: 23284610
[TBL] [Abstract][Full Text] [Related]
2. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
3. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
4. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
6. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.
Davatzikos C; Bhatt P; Shaw LM; Batmanghelich KN; Trojanowski JQ
Neurobiol Aging; 2011 Dec; 32(12):2322.e19-27. PubMed ID: 20594615
[TBL] [Abstract][Full Text] [Related]
7. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
[TBL] [Abstract][Full Text] [Related]
9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
10. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
12. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
[TBL] [Abstract][Full Text] [Related]
13. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors.
Cui Y; Liu B; Luo S; Zhen X; Fan M; Liu T; Zhu W; Park M; Jiang T; Jin JS;
PLoS One; 2011; 6(7):e21896. PubMed ID: 21814561
[TBL] [Abstract][Full Text] [Related]
14. Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.
Willette AA; Calhoun VD; Egan JM; Kapogiannis D;
Psychiatry Res; 2014 Nov; 224(2):81-8. PubMed ID: 25194437
[TBL] [Abstract][Full Text] [Related]
15. Spatial correlation maps of the hippocampus with cerebrospinal fluid biomarkers and cognition in Alzheimer's disease: A longitudinal study.
Liu G; Liu C; Qiu A;
Hum Brain Mapp; 2021 Jun; 42(9):2931-2940. PubMed ID: 33739550
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and prognosis of Alzheimer's disease using brain morphometry and white matter connectomes.
Wang Y; Xu C; Park JH; Lee S; Stern Y; Yoo S; Kim JH; Kim HS; Cha J;
Neuroimage Clin; 2019; 23():101859. PubMed ID: 31150957
[TBL] [Abstract][Full Text] [Related]
17. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
[TBL] [Abstract][Full Text] [Related]
18. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
19. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
